Anti-VEGF Therapy-Induced Accelerated Atherosclerosis: STEMI in a Young Adult

Area of Science:

• Cardiovascular Medicine
• Oncology
• Pharmacology

Background:

• Bevacizumab, an antiangiogenic monoclonal antibody, is used for central nervous system malignancies to manage cerebral edema.
• Long-term bevacizumab use is associated with potential cardiovascular risks, including endothelial dysfunction and hyperlipidemia.

Observation:

• A young patient with neurofibromatosis type 2 on long-term bevacizumab experienced ventricular fibrillation arrest due to myocardial infarction.
• Angiography revealed coronary artery disease, suggesting bevacizumab-induced endothelial injury and hyperlipidemia as contributing factors.

Findings:

• Bevacizumab therapy may accelerate the development of coronary atherosclerosis.
• Nitric oxide pathway disruption and proteinuria-induced dyslipidemia are key mechanisms involved.

Implications:

• This case highlights the critical need for monitoring cardiovascular health in patients receiving long-term bevacizumab.
• Early detection of atherosclerosis and aggressive management of lipid levels and blood pressure are crucial for mitigating risks.